Intra-Cellular Therapies Inc. (NASDAQ:ITCI) – Research analysts at SunTrust Banks decreased their FY2018 EPS estimates for shares of Intra-Cellular Therapies in a research note issued on Thursday. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings per share of ($2.52) for the year, down from their previous forecast of ($2.33). SunTrust Banks currently has a “Hold” rating and a $22.00 target price on the stock.
Several other equities research analysts have also recently weighed in on ITCI. Piper Jaffray Companies set a $10.00 price target on shares of Intra-Cellular Therapies and gave the stock a “hold” rating in a research report on Thursday, August 10th. Cantor Fitzgerald reiterated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, August 9th. BidaskClub cut shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. ValuEngine upgraded shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Finally, Cowen and Company reissued an “outperform” rating and set a $27.00 price objective (up previously from $20.00) on shares of Intra-Cellular Therapies in a research note on Friday. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $27.11.
Shares of Intra-Cellular Therapies (NASDAQ ITCI) traded down 2.30% on Monday, reaching $20.42. The company had a trading volume of 389,449 shares. The firm has a 50-day moving average price of $13.70 and a 200 day moving average price of $12.79. The firm’s market capitalization is $886.72 million. Intra-Cellular Therapies has a 1-year low of $7.85 and a 1-year high of $45.20.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.03 million. During the same period in the previous year, the business earned ($0.71) EPS. Intra-Cellular Therapies’s quarterly revenue was down 52.2% on a year-over-year basis.
Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Intra-Cellular Therapies in the second quarter valued at about $103,000. Bank of America Corp DE lifted its position in Intra-Cellular Therapies by 53.4% during the first quarter. Bank of America Corp DE now owns 9,660 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 3,363 shares during the period. Fred Alger Management Inc. bought a new stake in Intra-Cellular Therapies during the second quarter worth about $161,000. Nine Chapters Capital Management LLC bought a new stake in Intra-Cellular Therapies during the first quarter worth about $166,000. Finally, Voya Investment Management LLC lifted its position in Intra-Cellular Therapies by 16.0% during the second quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 2,338 shares during the period. Institutional investors and hedge funds own 71.79% of the company’s stock.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.